**Los Angeles**: Geoffrey Joyce, PhD, discusses the implications of proposed tariffs on pharmaceuticals, highlighting concerns over the US generic drug market’s vulnerability, supply chain disruptions, and the balance between domestic production incentives and potential price increases for consumers during a video interview with Pharma Commerce.
In a recent video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC), provided insights into how proposed tariffs on Chinese goods, particularly a potential 25% tariff on pharmaceuticals, could significantly influence the generic drug market in the United States.
Joyce explained that the dynamics between branded and generic drug markets differ fundamentally. With generics being considerably cheaper due to high competition among manufacturers, the proposed 10% tariff on these products might not dramatically alter their costs. This is largely because the majority of the expenses associated with generics are rooted in distribution rather than the actual manufacturing process.
The COVID-19 pandemic has brought to light the vulnerabilities in the US healthcare supply chain, specifically the reliance on international markets like China and India for essential generic medications. Following this recognition, there has been a growing movement to enhance domestic production capabilities. Joyce indicated that while a 25% tariff could potentially make manufacturing in the US more appealing, it could simultaneously lead to higher consumer prices. He stated that “generics are low-margin products,” implying that the economic incentives for manufacturers to maintain competitiveness could decrease, prompting resultant cost increases for consumers.
Furthermore, Joyce warned that the introduction of tariffs could disrupt existing supply chains. Despite the promotion of domestic production, the low-profit nature of generic drugs may encourage some international manufacturers to compromise on quality to maintain affordability, which raises concerns regarding the safety and efficacy of these medications. He referenced California’s unsuccessful attempt to foster a local generic drug industry as a case study reflecting the inherent difficulties associated with stimulating domestic production in a market characterised by slim profit margins.
During the interview, Joyce discussed the factors that make the generic drug market particularly vulnerable to supply chain disruptions. He noted that many generic products available in the US are sourced from a limited number of suppliers, primarily located in China and India. “If the FDA hypothetically shuts down a factory because of quality concerns in India or China, that can have enormous implications for the supply of that drug in the United States,” he elaborated. This dependency on a few manufacturers exposes the market to significant risks, especially if any of these suppliers encounter production issues.
Joyce also pointed out that while the generic drug market is often described as competitive, there have been instances in recent years where prices for some medications have spiked dramatically—by 100% or more—due to the exit of a competitor from the market, leading to less competition among remaining suppliers. Consequently, he emphasised that the generic drug market operates in a “delicate balance”, where interventions can yield unintended consequences, such as product exits from the market or decreased quality due to cost-cutting measures.
Overall, Joyce’s insights highlight the complex interplay between tariffs, domestic production incentives, pricing, and drug quality within the generic pharmaceuticals landscape. The future of the US generic drug market remains uncertain as stakeholders navigate these challenges, particularly with the backdrop of ongoing health policy changes and supply chain dynamics. A transcript of his full conversation with Pharma Commerce can be accessed for more detailed commentary on these issues.
Source: Noah Wire Services
Subscribe to Industry Updates
